Pharmacogenomics (PGx) Cancer Panel

Many chemotherapeutic agents and supportive care medications are impacted by specific variations in known genes. These genetic variations can contribute to medication efficacy and risk for side effects. Pharmacogenomic testing to guide prescribing, paired with clinical monitoring can impact outcomes for patients by reducing the time to therapeutic effect and reducing the risk of side effects.

This panel evaluates 12 genes associated with response to cancer chemotherapeutics and associated supportive care medications. These include antiemetics, antifungals, antineoplastics, fluoropyrimidines, immunosuppressants, platelet-stimulating agents, proton pump inhibitors, and uric acid inhibitors. Results from this test may help in predicting treatment efficacy and risk of side effects for these drugs.